{
    "id": 5198,
    "fullName": "FLT4 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "FLT4 (VEGFR3) amp indicates an increased number of copies of the Flt4 (Vegfr3) gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2324,
        "geneSymbol": "FLT4",
        "terms": [
            "FLT4",
            "CHTD7",
            "FLT-4",
            "FLT41",
            "LMPH1A",
            "LMPHM1",
            "PCL",
            "VEGFR-3",
            "VEGFR3"
        ]
    },
    "variant": "amp",
    "createDate": "04/23/2015",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6244,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with angiosarcoma harboring KDR (VEGFR2) and FLT4 (VEGFR3) amplification achieved stable disease for six months following treatment with Votrient (pazopanib) (PMID: 27160228).",
            "molecularProfile": {
                "id": 23076,
                "profileName": "FLT4 amp KDR amp"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5507,
                    "pubMedId": 27160228,
                    "title": "Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27160228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16628,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with angiosarcoma harboring KDR (VEGFR2) and FLT4 (VEGFR3) amplification developed progressive disease while on Nexavar (sorafenib) teatment (PMID: 27160228).",
            "molecularProfile": {
                "id": 23076,
                "profileName": "FLT4 amp KDR amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1816,
                "name": "angiosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5507,
                    "pubMedId": 27160228,
                    "title": "Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27160228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10800,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, analysis of radiation-associated breast angiosarcoma patients treated with Nexavar (sorafenib) demonstrated complete response in 22% (2/9) and partial response in 11% (1/9) of patients, with 30% (3/10) of the total group and 2 of 3 responders (3rd not evaluated) demonstrating FLT4 (VEGFR3) and MYC co-amplification (J Clin Oncol 30, 2012 (suppl; abstr 10019)).",
            "molecularProfile": {
                "id": 27804,
                "profileName": "FLT4 amp MYC amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 4511,
                "name": "breast angiosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8825,
                    "pubMedId": null,
                    "title": "Activity of sorafenib in radiation-associated breast angiosarcomas harboring MYC and FLT4 amplifications.",
                    "url": "http://meetinglibrary.asco.org/content/92128-114"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5011,
            "profileName": "FLT4 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 4012,
                    "name": "VEGFR3 Inhibitor",
                    "profileName": "FLT4 amp"
                },
                {
                    "id": 4011,
                    "name": "VEGFR Inhibitor (Pan)",
                    "profileName": "FLT4 amp"
                }
            ]
        },
        {
            "id": 23076,
            "profileName": "FLT4 amp KDR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27804,
            "profileName": "FLT4 amp MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}